Excerpt:
Akorn Inc [...] said late on Friday its Chief Executive Officer would retire following the drugmaker’s inability to salvage its takeover deal with Germany’s Fresenius SE [...]. The move comes after the Delaware Supreme Court on Friday upheld a decision by a lower court to allow Fresenius to walk away from its over $4 billion acquisition of Akorn that sent shares of the U.S generic drugmaker down more than 30 percent in regular trading. [...]